文献速递免疫规划传染病防控与疫情报告

印度儿童接种10价PCV(PNEUMOSIL®)后鼻咽部肺炎球菌携带状况:上市后横断面研究

Nasopharyngeal pneumococcal carriage in Indian children following 10-valent PCV (PNEUMOSIL®) introduction through India's universal immunization program: A post licensure cross-sectional study.
PubMed 文献 · Vaccine · 2025-12-23

该研究在印度浦那农村地区开展社区横断面观察,纳入700名健康儿童,比较完成PNEUMOSIL® 2+1程序接种者与未接种PCV者的鼻咽部肺炎球菌携带及疫苗血清型携带情况。

核心结论

  • PNEUMOSIL®接种可降低印度儿童疫苗血清型肺炎球菌携带,效果与其他PCV类似,可能有助于减少肺炎球菌疾病传播。

临床怎么用

  • 在印度免疫规划中使用PNEUMOSIL® 2+1程序可能降低疫苗血清型肺炎球菌携带,支持其作为公共卫生工具减少肺炎球菌疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reduction in the vaccine serotype (VT) carriage is a surrogate marker of pneumococcal vaccines protection. PNEUMOSIL®, a 10-valent pneumococcal conjugate vaccine (PCV) has been recently introduced in the national immunization program of India in a 2 + 1 schedule. Owing to scarcity of data about impact of PNEUMOSIL® vaccination on VT-carriage, the current study was conducted in Indian children to assess its impact. METHODS: This was a community-based cross-sectional observational study conducted between November 2022-March 2023 in rural areas of Pune, India. The study population included healthy children either fully vaccinated with PNEUMOSIL® 2 + 1 schedule through Universal Immunization Program or PCV-naïve. The vaccinated group was enrolled at least 4 months after receipt of the last PCV dose. Nasopharyngeal swabs were collected upon enrolment using World Health Organization methods in all children to isolate Streptococcus pneumoniae and identify serotypes using a Quellung test. The VT-carriage were compared between PCV-vaccinated and PCV-naïve using univariate and multivariate logistic regression. FINDINGS: The study enrolled 700 healthy children; 350 children aged 15-20 months previously fully vaccinated with PNEUMOSIL® 2 + 1 schedule through UIP and 350 PCV-naïve children aged 16-21 months. Overall S. pneumoniae carriage in PCV-vaccinated and PCV-naïve groups was 63·1 % (95 % CI 57·9 %-68·2 %) and 66·3 % (95 % CI 61·1 %-71·2 %), respectively (p = 0·384). VT-carriage occurred in 23·4 % (95 % CI 19·1 %-28·2 %) of vaccinated children and 30·9 % (95 % CI 26·1 %-36·0 %) of PCV-naïve participants (24·3 % reduction, p = 0·027). After adjusting for colonization risk factors, PNEUMOSIL® vaccination was associated with 32 % reduction in odds of VT colonization compared with PCV-naïve participants [OR = 0·68; 95 % CI 0·49-0·96]. INTERPRETATION: The observed reduction in VT-carriage amongst Indian children was comparable to that observed with other PCVs that have demonstrated marked declines in disease transmission. These results suggest PNEUMOSIL® could be an effective public health tool in decreasing pneumococcal disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sethna V, Apte A, Sanghavi S, et al. Nasopharyngeal pneumococcal carriage in Indian children following 10-valent PCV (PNEUMOSIL®) introduction through India's universal immunization program: A post licensure cross-sectional study. Vaccine. 2025. PMID: 41442867. doi:10.1016/j.vaccine.2025.128129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。